Our study identifies ADAM17 as a key cooperating factor and druggable target in oncogenic KRAS‐driven LAC and thus provides the rationale to employ ADAM17‐based therapeutic strategies for targeting oncogenic KRAS‐addicted cancers. Here, KRAS is linked to cancer.